Raymond James reiterates Strong Buy on Viking Therapeutic stock By Investing.com

The setup is less about the headline medical takeaway and more about positioning around scarcity of differentiated obesity assets. If the lean-mass narrative is neutralized, the market should keep rewarding drugs with the cleanest efficacy/safety and scale profile, which supports VKTX as a credible call option on the next phase of obesity share capture rather than a company-specific story. The bigger second-order effect is on the broader GLP-1 complex: if body-composition concerns fail to create product differentiation, then label expansion, supply reliability, and convenience remain the main battlegrounds, which favors incumbents with manufacturing depth over pure-plays.

For VKTX, the near-term risk is not the pre-print debate itself but execution into Phase 3 readouts over the next 6-18 months. In obesity biotech, multiple compression usually happens when traders realize that “good enough” efficacy is priced in before the first clean pivotal dataset, so any delay, tolerability issue, or weaker-than-expected placebo-adjusted weight loss could rapidly unwind the premium. Conversely, if the program keeps de-risking, the stock can rerate violently because the float is still primarily driven by binary clinical milestones rather than fundamentals.

The most interesting contrarian angle is that the market may be underestimating how little incremental differentiation the lean-mass debate actually provides across incretin drugs. If body composition is not a real wedge, then pricing and adherence become the real battleground, and that reduces the chance that smaller competitors win purely through “better quality loss” messaging. That is mildly supportive for the highest-conviction incumbent franchises, but it also means investor attention can swing back to who can produce the next credible dual-agonist with supply at scale.